Tvardi Therapeutics (TVRD) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing novel, oral small molecule therapies targeting STAT3 for fibrosis-driven diseases with unmet need.

• Lead candidate TTI-101 in Phase 2 for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC); TTI-109, a related STAT3 inhibitor, in preclinical development.

• Pipeline leverages proprietary expertise in STAT3 biology, aiming for disease-modifying therapies in fibrosis and oncology.

• Orphan drug designation for TTI-101 in IPF and HCC; Fast Track designation for TTI-101 in HCC.

Financial performance and metrics

• No revenue generated to date; company has incurred significant net losses since inception.

• Net loss of $29.4 million for 2024 and $9.6 million for Q1 2025; accumulated deficit of $101.8 million as of March 31, 2025.

• Cash and cash equivalents of $11.4 million and short-term investments of $10.9 million as of March 31, 2025.

• Received $23.8 million in cash from merger with Cara in April 2025.

• Ongoing significant R&D and G&A expenses; expects continued losses and need for additional capital.

Use of proceeds and capital allocation

• IPO is a resale registration for 2,084,117 shares by selling stockholders; company will not receive proceeds from these sales.

• Proceeds from prior financings and merger allocated to R&D, clinical trials, and general operations.

• Plans to seek additional funding through equity, debt, or strategic partnerships.